Tag: immune-stimulating antibody conjugate
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a...
San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...
Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at...
Veteran Executive Randall Schatzman, Ph.D. has been hired as the new Chief Executive Officer and a member of the board of directors of Bolt...